Intravascular administration of contrast media is an irreplaceable step of percutaneous coronary intervention. Since the latter is a very common procedure, contrast‑induced acute kidney injury (CI‑AKI) has become one of the most frequent causes of acute nephropathy, and a relevant prognostic impact of CI‑AKI has been observed. Some patient comorbidities and procedural characteristics have been identified as key risk factors of CI‑AKI. In this review, we discuss current evidence and future research directions on CI‑AKI prevention in patients undergoing percutaneous coronary intervention.